摘要
造血干细胞移植（HSCT）已成为多发性骨髓瘤（MM）的一线治疗方案.早期进行自体造血干细胞移植（ASCT）已成为年轻初发MM患者的标准治疗方法.在新药时代,新型制剂在HSCT前及HSCT后的巩固维持治疗中可提高HSCT疗效.对于治疗复发难治性MM,新药对HSCT的地位构成挑战.文章将总结近期HSCT在新药时代的临床研究,旨在明确新药时代HSCT在MM治疗中的地位.
Hematopoietic stem cell transplantation （HSCT） has become the frontline therapy for patients with multiple myeloma （MM）, and for young patients with primary MM, early autologous stem cell transplantation （ASCT） is a standard treatment. In the era of novel drugs, the application of new pharmaceutics in the consolidation and maintenance therapy before and after HSCT can improve the efficacy of HSCT. The novel agents pose a challenge to the status of HSCT in relapsed and refractory myeloma. This article summarizes the recent clinical studies of HSCT in the era of novel agents to clarify the role of HSCT in treatment of MM.
出处
《白血病．淋巴瘤》
CAS
2017年第8期505-508,共4页
Journal of Leukemia & Lymphoma
基金
国家自然科学基金（81500164）
关键词
多发性骨髓瘤
造血干细胞移植
药物
临床试用
Multiple myeloma
Hematopoietic stem cell transplantation
Drugs
investigational
